David S. Russell, MD, PhD

DownloadHi-Res Photo

Senior Director, Clinical Research, Translational Research

About

Titles

Senior Director, Clinical Research, Translational Research; Director, Clinical Research, Institute for Neurodegenerative Disorders; Assistant Clinical Professor

Biography

Dr. Russell is a neurologist specializing in movement disorders, dementias, and other neurodegenerative disorders. He is working full-time within a clinical research institute, devoted entirely to clinical research on diseases with major unmet needs. As a former director of the Yale Movement Disorders Consultation Clinic, he continues to work closely with other area neurologists and researchers to try to help improve the future for people with these diseases. Referrals to the Institute for Negenerative Disorders for potential research participation can be made most efficiently through the patient's treating neurologist or other physician.

Appointments

Psychiatry
Assistant Clinical Professor
Primary
Psychiatry
Neurology
Assistant Clinical Professor
Secondary
Neurology

Education & Training

Neurology Resident: Yale-New Haven Hospital (1995)

Chief Resident, Neurology: Yale-New Haven Hospital (1995)

Intern: Yale-New Haven Hospital (1992)

MD: Cornell University (1991)

PhD: Cornell University (1991)

BA: Oberlin College, Biology (1982)

IND

Research

Overview

Medical Subject Headings (MeSH)

Alzheimer Disease; Huntington Disease; Movement Disorders; Neurodegenerative Diseases; Parkinson Disease

ORCID
0000-0002-9105-2943

Research at a Glance

Yale Co-Authors

Frequent collaborators of David S. Russell's published research.

Gilles Tamagnan, PhD
View Full Profile
View 6 Common Publications
Catharine Duman, PhD
View Full Profile
View Common Publication
Stephen Strittmatter, MD, PhD, AB
View Full Profile
View Common Publication

Publications

2024

Glutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001)
Brasic J, Nandi A, Russell D, Jennings D, Barret O, Slifer K, Sedlak T, Seibyl J, Berry-Kravis E, Wong D, Budimirovic D. Glutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204347.
Peer-Reviewed Original Research

2023

Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration
Koga S, Metrick M, Golbe L, Santambrogio A, Kim M, Soto-Beasley A, Walton R, Baker M, De Castro C, DeTure M, Russell D, Navia B, Sandiego C, Ross O, Vendruscolo M, Caughey B, Dickson D. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathologica Communications 2023, 11: 88. PMID: 37264457, PMCID: PMC10236843, DOI: 10.1186/s40478-023-01584-z.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2022

2021

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
Kielbasa W, Shcherbinin S, Goldsmith P, Phipps K, Biglan K, Mancini M, Russell D, Constantinescu C, Gunn R, Nuthall H, Mergott D, Lowe S, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057774.
Peer-Reviewed Original Research
Concepts
MEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME
Brasic J, Budimirovic D, Nandi A, Russell D, Jennings D, Barret O, Martin S, Sllifer K, Berry-Kravis E, Wong D. MEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME. Journal Of The American Academy Of Child & Adolescent Psychiatry 2021, 60: s257. DOI: 10.1016/j.jaac.2021.09.413.
Peer-Reviewed Original Research
Concepts
Reduced Metabotropic Glutamate Receptor Subtype 5 in Fragile X Syndrome (4378)
Brasic J, Nandi A, Russell D, Jennings D, Barret O, Mathur A, Slifer K, Sedlak T, Martin S, Brinson Z, Vyas P, Seibyl J, Berry-Kravis E, Wong D, Budimirovic D. Reduced Metabotropic Glutamate Receptor Subtype 5 in Fragile X Syndrome (4378). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.4378.
Peer-Reviewed Original Research

2020

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human
Shcherbinin S, Kielbasa W, Dubois S, Lowe S, Phipps K, Tseng J, Kevin D, Natanegara F, Warner S, Dreyfus N, Lindsay‐Scott P, Hawk M, McDonald N, Zhang X, Gilmore J, Biglan K, Mergott D, Russell D, Gunn R, Constantinescu C, Nuthall H, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.040558.
Peer-Reviewed Original Research
Concepts

See All Publications

Links & Media

News

July 15, 1999
National Alliance for Research on Schizophrenia and Depression
Read more

Related Links
- Institute for Neurodegenerative Disorders

Get In Touch

Contacts

Appointment Number

Office Fax Number

Mailing Address

Psychiatry

Temple Medical Center, 60 Temple St., Suite 8B

New Haven, CT 06510

United States